Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Nilotinib has a higher binding affinity and selectivity for BCR-ABL with respect to imatinib and is an effective treatment of chronic myeloid leukemia (CML) after imatinib failure. In a phase 2 study, 73 early chronic-phase, untreated, Ph(+) CML patients, received nilotinib at a dose of 400 mg twice daily. The primary endpoint was the complete cytogenetic response (CCgR) rate at 1 year. With a median follow-up of 15 months, the CCgR rate at 1 year was 96%, and the major molecular response rate 85%. Responses were rapid, with 78% CCgR and 52% major molecular response at 3 months. During the first year, the treatment was interrupted at least once in 38 patients (52%). The mean daily dose ranged between 600 and 800 mg in 74% of patients, 400 and 599 mg in 18% of patients, and was less than 400 mg in 8% of patients. Dose interruptions were mainly due to nonhematologic and biochemical side effects. Myelosuppression was irrelevant. One patient progressed to blastic crisis after 6 months; one went off-treatment for lipase increase grade 4 (no pancreatitis). Nilotinib is safe and very active in early chronic-phase CML. These data support a role for nilotinib for the frontline treatment of CML. This study was registered at ClinicalTrials.gov as NCT00481052.

[1]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2009, Leukemia.

[2]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.

[3]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[4]  M. Baccarani,et al.  High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party , 2008 .

[5]  M. Pirmohamed,et al.  Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters , 2008 .

[6]  T. Lion,et al.  CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase. , 2008 .

[7]  R. O’Keefe,et al.  Prostaglandin E2 (PGE2) Treatment Rapidly Increases the Fraction of Non-Dividing Hematopoietic Stem Cells (HSCs) , 2008 .

[8]  H. Mcdonald,et al.  160. ALIGNMENT TO ACCP PROPHYLAXIS GUIDELINES AND VTE OUTCOMES IN THR AND TKR PATIENTS , 2008 .

[9]  M. Goodell,et al.  CD81 Is Essential for HSC Self-Renewal through Suppressing Proliferation , 2008 .

[10]  R. Larson,et al.  Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. , 2008 .

[11]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[12]  P. Lin,et al.  Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. , 2008, Blood.

[13]  P. Valent.  Emerging stem cell concepts for imatinib‐resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease , 2008, British journal of haematology.

[14]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Augustin,et al.  Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. , 2008, Blood.

[16]  C. Jamieson,et al.  Chronic myeloid leukemia stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kantarjian,et al.  Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP) , 2008 .

[18]  G. Martinelli,et al.  CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate , 2008, Leukemia.

[19]  J. Apperley.  Part II: management of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.

[20]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[21]  J. Apperley.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.

[22]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[23]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[24]  Martin C. Müller,et al.  An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. , 2007, Haematologica.

[25]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[26]  H. Kantarjian,et al.  New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance , 2006, Annals of Internal Medicine.

[27]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[28]  M. Mancini,et al.  A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP). , 2006 .

[29]  L. Scapozza,et al.  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. , 2006, Cancer research.

[30]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[31]  Susan O'Brien,et al.  Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. , 2006, Blood.

[32]  J. Goldman,et al.  Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia , 2006, Leukemia.

[33]  P. Manley,et al.  OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. , 2006, Blood.

[34]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[35]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[36]  J. Mestan,et al.  AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia , 2005, Clinical Cancer Research.

[37]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[38]  T. Holyoake,et al.  Punish the parent not the progeny. , 2005, Blood.

[39]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[40]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[41]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[42]  U. Reinhold,et al.  FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib , 2003, Leukemia.

[43]  M. Slovak,et al.  Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. , 2003, Blood.

[44]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[45]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[46]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[47]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[48]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[49]  J. Hasford,et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.

[50]  J. Friedman.  'Drug holidays' in the treatment of Parkinson's disease. A brief review. , 1985, Archives of internal medicine.

[51]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[52]  N. Rouas-Freiss,et al.  molecule Beyond the increasing complexity of the immunomodulatory HLA-G , 2008 .

[53]  R M Stone,et al.  Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib , 2008, Leukemia.

[54]  G. Saglio,et al.  Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories , 2008, Leukemia.

[55]  P. Erben,et al.  Resistance to targeted therapy in chronic myelogenous leukemia. , 2007, Seminars in hematology.

[56]  S. Kimura,et al.  INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. , 2007, Blood.

[57]  M. Baccarani,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia. , 1984, Blood.